Neurizon Therapeutics (FRA:ECQ0) Interest Expense : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Neurizon Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Neurizon Therapeutics's interest expense for the six months ended in Dec. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Neurizon Therapeutics's Operating Income for the six months ended in Dec. 2024 was € -5.47 Mil. Neurizon Therapeutics's Interest Expense for the six months ended in Dec. 2024 was € 0.00 Mil. Neurizon Therapeutics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Neurizon Therapeutics Interest Expense Historical Data

The historical data trend for Neurizon Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurizon Therapeutics Interest Expense Chart

Neurizon Therapeutics Annual Data

Trend

Jun01

Jun02

Jun03

Jun04

Jun05

Jun24

Interest Expense

Get a 7-Day Free Trial

-0.05

-0.07

-0.03

-0.02

Neurizon Therapeutics Semi-Annual Data
	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Jun24	Dec24
Interest Expense	Get a 7-Day Free Trial															-0.03	-0.03	-	-	-

Neurizon Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Neurizon Therapeutics (FRA:ECQ0) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Neurizon Therapeutics's Interest Expense for the six months ended in Dec. 2024 was €0.00 Mil. Its Operating Income for the six months ended in Dec. 2024 was €-5.47 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2024 was €0.00 Mil.

Neurizon Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Neurizon Therapeutics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Neurizon Therapeutics Ltd has no debt.

Neurizon Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NUZ:Australia

Address

96-100 Albert Road, Level 4, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.neurizon.com

Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Neurizon Therapeutics Headlines

No Headlines